Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

Completed · Phase 2 · Has a placebo group

Conditions studied: Plaque Psoriasis

In brief

There are cells in the skin and blood of humans with chronic moderate to severe plaque psoriasis with specific activities that may determine the effectiveness of treatment. These activities may be described by obtaining samples of skin and blood and analyzing them using a variety of tests.

Key facts

Study ID

NCT01710046

Run by

Pfizer

People needed

12

Starts

2013-03-01

Expected to finish

2013-11-01

Last updated by the study team

2015-04-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults over 18 years of age with a diagnosis of chronic moderate to severe plaque psoriasis for at least 12 months; in generally good health; on stable dose of non-prohibited medications; able to stop current psoriasis therapy (systemic or topical) for several weeks prior to and during study participation.

You may not qualify if…

• Serious underlying disease including viral disorders such as hepatitis or HIV or skin condition that would interfere with skin biopsies or evaluation of psoriasis; conditions that could interfere with drug absorption after oral administration; history of malignancy or auto-immune disease.
• Use of oral or injected corticosteroids (steroids).

Where it is running

• Dermatology Research Associates — Los Angeles, California, United States
• Olympian Clinical Research — Tampa, Florida, United States
• Menter Dermatology Research Institute — Dallas, Texas, United States
• Center for Clinical Studies — Houston, Texas, United States
• Center for Clinical Studies — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.